Texas

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Lawmakers continue to hear concerns over drug prices, as well as proposals to fix the issue.

First reported by the San Antonio Business Journal, the company will cut about 265 employees, 200 from its Alamo City site and the rest from its Charlotte facility. The cuts are part of a restructuring and will be handled over time, rather than all in one fell swoop of pink slips.

Alexander (Sasha) Opotowsky, associate professor at Harvard Medical School and a cardiologist at Boston Children’s Hospital and Brigham and Women’s Hospital took time out to speak with BioSpace about advances in heart health, congenital heart disease (CHD), biopharma, and the Adult Congenital Heart Association (ACHA).

In this week’s edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.

Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation.

During the president’s annual address to Congress and the nation, Trump said that as a result of his administration’s efforts to lower the costs of prescription drugs, “in 2018 drug prices experienced their single largest decline in 46 years.”

Investors are not happy after Austin, Texas-based Pain Therapeutics announced that it was no closer to seeing its drug candidate Remoxy ER, an abuse-deterrent, extended-release gel formulation of oxycodone, approved by the U.S. Food and Drug Administration.

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. What are the unique benefits your life sciences employer offers?

Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.